3 0 1 t e c h n i c a l r e p o r t s Technologies that enable the rapid detection and localization of bacterial infections in living animals could address an unmet need for infectious disease diagnostics. We describe a molecular imaging approach for the specific, noninvasive detection of S. aureus based on the activity of the S. aureus secreted nuclease, micrococcal nuclease (MN). Several short synthetic oligonucleotides, rendered resistant to mammalian serum nucleases by various chemical modifications and flanked with a fluorophore and quencher, were activated upon degradation by purified MN and in S. aureus culture supernatants. A probe consisting of a pair of deoxythymidines flanked by several 2′-O-methyl-modified nucleotides was activated in culture supernatants of S. aureus but not in culture supernatants of several other pathogenic bacteria. Systemic administration of this probe to mice bearing S. aureus muscle infections resulted in probe activation at the infection sites in an MN-dependent manner. This new bacterial imaging approach has potential clinical applicability for infections with S. aureus and several other medically important pathogens.
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Diagnosis of focal bacterial infections, such as osteomyelitis, septic arthritis and pyomyositis, initially entails the evaluation of several nonspecific symptoms, including pain, swelling and fever [1] [2] [3] . Definitive evidence of infection and identification of the causative bacterial species can only be obtained via tissue biopsy and culture. Whereas focal bacterial infections can be life-threatening situations in which time is of the essence, such diagnostic procedures typically consume many hours to days. Moreover, current diagnostic approaches are prone to false negative results 4 . Rapid, sensitive and noninvasive molecular imaging assays for bacterial infections could thus address an unmet need for infectious disease diagnostics.
Preclinical development of molecular imaging approaches for bacterial infections offers hope for the future availability of such technologies [5] [6] [7] [8] [9] [10] [11] . Although promising, none of these approaches provides a platform for the development of species-selective imaging probes for multiple bacterial species. Bacterial imaging probes that provide species-specific information are desirable because they could facilitate the rapid administration of appropriate therapy (for example, antibiotic treatment tailored for the species) in clinical settings. Nucleases, which have widespread expression and diversity, are one category of proteins that could be used to specifically identify a variety of bacterial species 12 . As degrading enzymes, nucleases can be detected with activatable probes 13 . Activatable probes release their signal (usually fluorescence) only upon encountering their target molecule, which greatly increases the sensitivity of target detection and thus provides an important advantage over nonactivatable probes 14 . We recently reported that several as-yet-unidentified nucleases produced by a species of mycoplasma (Mycoplasma fermentans) can efficiently digest chemically modified oligonucleotides that are resistant to degradation by mammalian nucleases 15 . This finding suggested the use of chemically modified oligonucleotides as the basis of activatable probes for the detection of Mycoplasma fermentans.
We began this study by asking whether bacterial pathogens that are responsible for substantial morbidity and mortality might also express nucleases capable of degrading chemically modified oligonucleotides. Such nucleases could potentially be used as the probe-activating component of an imaging approach for pathogenic bacteria. We focused our efforts on S. aureus, the most common cause of many types of focal infections in humans 1-3 . S. aureus secretes a nuclease known as MN, a very well-studied enzyme that is among the first proteins extensively investigated with structure and folding studies [16] [17] [18] . MN exhibits robust DNase and RNase activities and is active on both single-and double-stranded DNA substrates, and its nuclease activity has been used to classify bacterial isolates for decades 17, 19 .
Here we report the noninvasive detection of S. aureus infections with a quenched fluorescent oligonucleotide probe that we tailored to be specifically activated by MN. The probe is expected to be both nontoxic and inexpensive, and it enables infection localization in less than an hour when administered at low doses. These elements could facilitate the translation of this infection imaging approach into clinical practice.
RESULTS
We sought a short oligonucleotide substrate that is both sensitive to MN and resistant to serum nucleases. Such an oligonucleotide could form the basis of a quenched fluorescent imaging probe that is specifically activated (fluorescence is unquenched) upon digestion by MN 13 . Because the susceptibility of chemically modified oligonucleotide substrates to MN digestion is poorly understood, we tested the ability of MN to degrade oligonucleotide substrates with chemical modifications that are known to promote resistance to degradation by mammalian serum nucleases 20 . To facilitate the subsequent development of imaging probes, we tested the various oligonucleotide compositions in a quenched fluorescent probe format: short (10-to 12-mer) oligonucleotides flanked with a 5′ fluorophore (fluorescein amidite (FAM)) and 3′ quenchers (ZEN and Iowa Black RQ) 13, 15 .
One such probe, made with an oligonucleotide composed exclusively of locked nucleic acid-modified nucleotides, was not digested by MN (F.J.H., unpublished observation), whereas oligonucleotides composed exclusively of 2′-fluoro-or 2′-O-methyl-modified nucleotides were relatively weak substrates (data not shown) 20, 21 . Next, we compared the MN and serum nuclease susceptibility of RNA oligonucleotides composed of 2′-fluoro-or 2′-O-methyl-modified pyrimidines and unmodified purines with that of a DNA oligonucleotide, as DNA is the preferred substrate for MN among unmodified nucleic acids (see Table 1 for probe sequences and modifications) 17 . A 1 U µl −1 MN concentration yielded complete or near-complete digestion of these oligonucleotides after short incubations and was thus used as a normalization control for the assays. More dilute MN (0.1 U µl −1 ) provided an intermediate degree of digestion after 15 or 60 min, thus enabling assessment of the relative degree of digestion of the substrates. The DNA probe was digested by MN (in PBS supplemented with CaCl 2 and MgCl 2 ) more efficiently than either the 2′-fluoro-or 2′-O-methyl-modified pyrimidine RNA oligonucleotides, but was, as expected, also substantially digested in serum ( Fig. 1a) . In contrast, the 2′-fluoro-and 2′-O-methylmodified pyrimidine RNA oligonucleotides were more stable in serum but less efficiently digested by MN. A second-generation probe, composed of a pair of deoxythymidines flanked by several 2′-Omethyl-modified nucleotides, was designed to maximize sensitivity to MN, which is known to efficiently digest oligonucleotides with deoxythymidine nucleotides while also resisting serum nuclease degradation 22 . This 'TT probe' was substantially more sensitive to MN digestion than the other chemically modified oligonucleotides tested, and it also exhibited robust serum stability ( Fig. 1a) . Probes in which AT or AA were substituted for the central TT exhibited reduced sensitivity for MN digestion and were not pursued with further experiments (Supplementary Fig. 1 ). Measurement of TT probe activation by MN (0.05 U µl −1 ) as a function of time revealed rapid activation kinetics, with an activation half-time of 7.7 min ( Supplementary  Fig. 2 ). The TT probe exhibited comparable activation by MN in the Table 1 Nuclease probe sequences and modifications context of mouse or human serum and buffer (PBS), suggesting its in vivo utility ( Supplementary Fig. 3) .
To evaluate the activation of these probes in the context of the complex mixture of S. aureus-secreted factors, we incubated the probes with culture supernatants of the Newman and UAMS-1 strains of S. aureus (Fig. 1b , also see Supplementary Table 1 for bacterial strains used in this study). The TT probe was completely digested after a 60-min incubation in either supernatant (Fig. 1b) . This was not unexpected because we previously measured extracellular MN levels of 0.45-0.6 U µl −1 in cultures of these strains 23 . The digestion observed here was primarily mediated by MN, as incubation of the TT probe in supernatants of MN-negative versions of each strain yielded minimal probe activation ( Fig. 1b) 23, 24 . In summary, among the serum nuclease-resistant oligonucleotides tested, the TT probe clearly exhibited the greatest sensitivity to digestion by MN, both in purified form and in culture supernatants.
The utility of visible-light fluorophores, such as fluorescein (excitation/emission (ex/em), 494/521 nm), for in vivo imaging is severely limited by tissue autofluorescence and scattering of visible light 25 . In contrast, tissue penetration of light with substantially longer wavelengths, especially within the near-infrared (NIR) range, is much greater, and tissue autofluorescence with NIR is minimal 25 . Indeed, fluorescence imaging with NIR light is estimated to be feasible at tissue depths of 7-14 cm (ref. 25) . To prepare an MN-detecting imaging probe based on the TT probe that would be more suitable for in vivo imaging, we substituted Cy5.5 (ex/em: 685/706 nm), a fluorophore with emission in the NIR range, for the FAM moiety used in the initial TT probe version. The fluorescence of this intact probe was weak, but after digestion with MN, its fluorescence was comparable to that of a control probe synthesized without fluorescence quenchers ( Fig. 2a) .
Next, we sought to determine whether this probe could enable the detection of a focal S. aureus infection in mice. To provide an independent measure of bacterial location and burden in infected animals, we incorporated the lux operon of Photorhabdus luminescens into wild-type S. aureus strain Newman and an MN-negative mutant [26] [27] [28] . Mice with unilateral thigh muscle infections (pyomyositis) of these modified bacteria exhibited luminescence that co-localized with clinical swelling and gross lesions ( Fig. 2d,e and Supplementary  Fig. 4 ). Magnetic resonance imaging of infected mice provided an additional measure of the lesions in vivo (Supplementary Fig. 5 ). Tail vein administration of 3 nmol (~1 mg per kg body weight) of Cy5.5-labeled TT probe (probe was administered 48 h after bacterial inoculation) yielded fluorescence at the infection sites that was evident as early as 15 min after injection (Fig. 2d) . The subsequent accumulation of activated probe over time is possibly a result of the hydrophobic nature of the Cy5.5 dye, which may retard its clearance. In contrast to the probe activation seen in infected animals, injection of the Cy5.5-labeled TT probe into uninfected mice (Fig. 2b) did not yield lateralized probe activation. Administration of the unquenched TT probe into uninfected animals resulted in a globally high fluorescence that began to decline only 1-2 h after injection ( Fig. 2c and  Supplementary Fig. 6 ). Finally, the probe activation seen at wildtype S. aureus infection sites was primarily due to the activity of MN, as substantially less TT probe activation was seen at MN-negative S. aureus infection sites ( Fig. 2e) . We found comparable luminescence levels in the wild-type and MN-negative S. aureus infections, indicating comparable bacterial loads in these experimental groups (Supplementary Fig. 7) . The weak TT probe activation observed in the MN-negative infections probably results from a distinct S. aureus nuclease that has previously been described 29 . Weak TT probe activation observed upon incubation with MN-negative S. aureus cell suspensions (data not shown) is consistent with this conclusion. There were no overt differences in the extent of bacterial colonization, necrosis or inflammation between the wild-type and MN-negative infections in histological sections or in levels of circulating neutrophils in mice bearing these infections ( Supplementary  Figs. 8 and 9) . Thus, the probe activation seen in the wild-type S. aureus-infected animals does not seem to be related to the inflammatory response to the infections. Quantification of probe fluorescence levels at the infection sites and in the uninfected legs of TT probe-injected mice yielded an approximately fourfold target-to-background ratio at 45 min after probe injection (Supplementary Fig. 10) .
Although these results indicate that MN activates the TT probe at S. aureus infection sites in vivo, we observed that much of the probe fluorescence extended beyond the boundary of the bioluminescence signal. A simple and plausible explanation is that the intravenously administered probe may have limited access to the infection site in the setting of our pyomyositis infection model. Indeed, when bacterial infections progress to the stage of tissue necrosis, liquefaction or abscess formation, penetration of intravenously administered agents (including antibiotics) is limited and access becomes problematic 30 . To explore this possibility, we injected (via tail vein) the unquenched TT probe into mice with S. aureus-infected thigh muscles. The mice were subsequently euthanized and dissected to provide a clearer picture of the infection sites. The unquenched probe appeared to have very limited access to the infection site ( Fig. 2f) . We also observed activation of the TT probe adjacent to the infection site after killing and dissection (Fig. 2g) . Moreover, histological examination of S. aureus-infected mouse thigh muscles (Supplementary Fig. 11 ) revealed lesions with substantial necrosis, an observation consistent with the notion that the infection sites have reduced blood perfusion and, consequently, reduced probe access. These results suggest that the probe activation seen in infected animals ( Fig. 2d,g) may have resulted from the probe encountering MN that had leaked out of the primary infection site. The penetration rate that MN (a ~17 kDa protein) would need to exhibit in the muscle tissue to account for the probe activation observed (~4 mm in 48 h, or 0.08 mm h −1 ) is well within the limits found by others who have studied macromolecular penetration of muscle tissue (0.39-0.6 mm h −1 for 20-kDa dextran) 31 . In summary, the TT probe detected the presence of S. aureus, despite having only limited access to the region where the bacteria, and presumably MN, were most concentrated.
The clinical diagnostic value of assays that noninvasively detect bacterial infections such as pyomyositis, septic arthritis, etc., will depend, in part, on their ability to simultaneously identify the type of bacteria present. We thus sought to determine whether the TT probe, or any of the others we have tested, might also be activated by nucleases produced by other bacterial pathogens that cause some of the same types of infections as S. aureus. Of the culture supernatants of seven such bacterial species tested (Supplementary Table 2 lists colonyforming unit (CFU) ml −1 values), none substantially digested the TT probe, whereas Staphylococcus lugdunensis and Streptococcus agalactiae (group B Streptococcus) supernatants both digested the probes that included 2′-fluoro-modified nucleotides (Fig. 3a) . The lack of activation of the DNA probe by culture supernatants of bacteria known to secrete DNases (for example, S. agalactiae), possibly reflects an incompatibility of the particular sequence used in this probe with the secreted DNases. Of the bacterial cell suspensions of the cultures tested, only that of S. lugdunensis (an emerging pathogen of the same genus as S. aureus) produced any appreciable digestion of the TT probe (~25%) npg in a 1-h incubation (Fig. 3b) . Bacterial cell suspensions of S. agalactiae and Streptococcus pneumoniae both digested the probes that included 2′-fluoro-modified nucleotides (Fig. 3b) , possibly resulting from the activity of surface-localized nucleases. Together, these results demonstrate a high degree of nuclease specificity for the TT probe.
DISCUSSION
The imaging tools that are currently available for diagnosing bacterial infections cannot directly detect bacteria or material derived from them; they are used to measure downstream consequences of infections, such as tissue destruction or inflammatory responses. Such assays provide no direct evidence of either the type or the presence of bacteria at sites of potential infections. As a result of these limitations, physicians currently depend heavily on a variety of nonspecific criteria together with biopsy and culture (which is time consuming) to diagnose infections. In this proof-of-concept study, we developed an activatable probe that enables the noninvasive imaging of S. aureus infections in mice in less than an hour. To the best of our knowledge, the present study is the first to demonstrate the noninvasive imaging of a disease condition in animals with a nuclease-activated probe. npg Our exploration of the substrate specificity of MN provided a framework for the design of a probe that would be efficiently activated by MN without being susceptible to serum nucleases. The incorporation of unmodified deoxythymidines into the TT probe was intended to make it highly sensitive to MN digestion, and in vitro probe activation assays with purified MN indicate that MN does, in fact, efficiently activate the probe. Culture supernatants of two common strains of S. aureus also activate the probe. The activation of the TT probe by S. aureus (supernatants or in infected animals) can be attributed to MN activity because we saw minimal probe activation in experiments with an S. aureus mutant that does not express MN. Notably, the TT probe is resistant to degradation by mouse and human serum nucleases, probably owing to the 2′-Omethyl-modified nucleotides that flank the central deoxythymidines, as this modification is known to provide a high degree of resistance to serum nucleases. The nucleases present in the culture supernatants of our panel of additional pathogenic bacterial species failed to digest any of the oligonucleotides with 2′-O-methyl-modified nucleotides. The inclusion of the flanking 2′-O-methyl-modified nucleotides in the TT probe may thus be responsible for its resistance to these other bacterial nucleases, as well. In any case, the fact that this probe is preferentially activated by MN suggests that the imaging approach described here has the potential not only to determine the location of bacterial infections but also to indicate the type of bacteria that may be present.
Several preclinical bacterial imaging approaches can detect bacteria nonspecifically [6] [7] [8] 10, 11 . Our approach and the prothrombin-based approach of Panizzi et al. 9 provide a means of specifically detecting S. aureus. Whereas nonspecific bacterial detection has the advantage of detecting a wide variety of infections, species-specific detection can potentially guide physicians in antibiotic selection at an early stage in the diagnostic process and thus provides complementary, and highly valuable, information. In contrast to the prothrombin-based approach, the nuclease-activated approach provides a blueprint for the species-specific detection of a variety of medically important bacterial pathogens. The present study therefore represents a proof-of-concept study that may lead to a new category of species-specific, activatable imaging probes for bacterial infections. The broad diversity of nuclease structures and enzymatic mechanisms supports the notion that specific probes can be engineered for many additional target nucleases 12 . Indeed, the distinct substrate specificities of the other (non-S. aureus) bacterial nucleases tested and the fact that some of these can digest oligonucleotides that are resistant to serum nucleases suggests the broader applicability of the approach. Although this approach is applicable only to pathogens that produce targetable nucleases, there are, nonetheless, several prominent pathogens besides S. aureus that are known to produce robust nuclease activity [32] [33] [34] . The wide variety of existing synthetic nucleotide modifications is also likely to facilitate the engineering of additional specific probes 20 .
The bacterial detection approach we describe here seems well suited for clinical translation. The probes are expected to be nontoxic because the oligonucleotide portion is composed only of naturally occurring modified (2′-O-methyl) and DNA nucleotides. A recent preclinical toxicity study of IRDye 800CW, an NIR fluorophore that would be an attractive alternative to Cy5.5 for clinical translation of the approach (it is excited and emits at longer wavelengths, which yield better tissue penetration), found that this fluorophore has low toxicity in rats 35 . TT probe activation was detected at infection sites after administration of low doses (~1 mg per kg body weight), further increasing the likelihood that toxic effects can be avoided. Current nucleic acid synthesis and conjugation technologies are sufficiently advanced to make the large-scale good manufacturing practice synthesis of such probes both feasible and economical. Although deep-tissue infections (for example, kidney abscesses) are beyond the reach of current noninvasive optical imaging approaches, there remains a wide variety of bacterial infections that are shallow enough to be detectable with NIR fluorescence imaging (for example, many joint and bone infections). Ongoing efforts by several groups to translate NIR imaging approaches to the clinic may make NIR clinical imaging instrumentation commonplace in clinical settings in the near future, thus providing an infrastructure for the accommodation of NIR-based bacterial imaging diagnostic approaches [36] [37] [38] [39] . For these reasons and because this approach would address an important unmet clinical need, we anticipate its clinical translation in the coming years.
METhODS
Methods and any associated references are available in the online version of the paper. Table 1 for probe details) by culture supernatants (a) or cell suspensions (b) of various pathogenic bacterial species. Each of the indicated probes was incubated with 1 U µl −1 MN (positive control) in DPBS or with 90% of culture supernatants or concentrated and washed cell suspensions of the indicated bacterial species (prepared as described in the Online Methods) at 37 °C. Mean fluorescence values of all reactions (measured in triplicate) with a given probe were normalized to the mean fluorescence measured with digestion of the probe with 1 U µl −1 MN. Error bars represent s.d. of the triplicate fluorescence measurements.
npg t e c h n i c a l r e p o r t s images acquired 45 min after TT probe administration. The following three groups of mice were included in the analysis: uninfected mice, S. aureusinfected mice and MN-negative S. aureus-infected mice. We determined target-to-background ratios as follows. For infected animals, the fluorescence measured within an ROI placed over the probe-activation site of the infected leg was divided by fluorescence measured within an ROI placed over the contralateral uninfected leg. For each uninfected mouse, we calculated the ratio of fluorescence within ROIs of uninfected versus contralateral uninfected leg. We subtracted the tissue autofluorescence level (measured within each ROI in the background fluorescence image (taken before probe administration)) from each of the corresponding ROI fluorescence values measured at the 45-min time point before the ratio calculations.
Magnetic resonance imaging of infected mice. We carried out magnetic resonance imaging (MRI) with a 4.7-Tesla Varian Unity/INOVA small-bore scanner with a 25-mm diameter transmit/receive coil. First, we anesthetized the mice with isoflurane (3% induction, 1.5% maintenance) and transferred them to the scanner. Following localizer scans, we acquired three sets of T2-weighted fast spin-echo scans (one each in axial, coronal and sagittal orientations). Pulse sequence parameters were TR/TE = 2,000/60 ms, echo train length = 8, slice thickness of 0.8 mm, and in-plane resolution of 0.16 mm over a 256 × 256 acquisition matrix with six signal averages for a scan time of about 8 min per orientation. Overall scan time was about 30 min for each mouse.
Blood counts. For blood collection, we anesthetized mice with ketamine/ xylazine and collected at least 150 µl blood from each mouse via submandibular venous puncture into an EDTA tripotassium salt multivette (Multivette 600 K3E; Sarstedt). We measured complete blood counts (CBCs) from undiluted blood samples within 30 min of collection using a Sysmex XT-200i Automated Hematology Analyzer (Sysmex America). 
